Fennec Pharmaceuticals
FENC
31 hedge funds and large institutions have $65.7M invested in Fennec Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 3 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
61% more capital invested
Capital invested by funds: $40.7M → $65.7M (+$25M)
15% more funds holding
Funds holding: 27 → 31 (+4)
8.38% more ownership
Funds ownership: 42.54% → 50.92% (+8.4%)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$187K |
| 2 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$154K |
| 3 |
Renaissance Technologies
New York
|
+$128K |
| 4 |
Goldman Sachs
New York
|
+$76.4K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
+$68.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$377K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$124K |
| 3 |
6CM
683 Capital Management
New York
|
-$115K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$112K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$16.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $2K | +$1.13K | +210 | +159% |
|
|
WQ
27
Wealth Quarterback
Toms River,
New Jersey
| $1K | +$34.3K | +6,380 | New |
|
28
BNP Paribas Financial Markets
Paris,
France
| $402 | -$7.27K | -1,354 | -96% |
|
|
FDCDDQ
29
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $7 | – | – | – |
|
30
Citigroup
New York
| – | -$6K | -1,308 | Closed |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3.91K | -728 | -90% |
|
32
JP Morgan Chase
New York
| – | -$1K | -110 | Closed |
|
FENC Hedge Fund Activity: Q4 2019 in Review
31 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2019, worth a combined $65.7M — up 61% from $40.7M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FENC positions and 3 closed out — a net gain of 4 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $187K. The largest seller was Granahan Investment Management, cutting an estimated $377K.
- 31 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2019, up from 27 in Q3 2019.
- Funds reported $65.7M of Fennec Pharmaceuticals stock for Q4 2019, up 61% quarter-over-quarter.
- 7 funds opened new Fennec Pharmaceuticals positions in Q4 2019 and 3 closed out, a net change of +4 holders.
- The largest Fennec Pharmaceuticals buyer in Q4 2019 was Susquehanna International Group, an estimated $187K added.
- The largest Fennec Pharmaceuticals seller in Q4 2019 was Granahan Investment Management, an estimated $377K sold.
Based on aggregated 13F filings for Q4 2019.